Latest California Healthline Stories
Everything You Need to Know About Paxlovid — Especially, Should You Take It?
Paxlovid has eclipsed other available therapies for preventing life-threatening covid symptoms in high-risk patients. But even as doctors praise its effectiveness, many say they have unanswered questions about prescribing the drug and want more and better data about it.
To Stem Monkeypox’s Spread, Health Departments Tap Into Networks of Those Most at Risk
Although the disease is currently spreading almost exclusively among men who have sex with men, some cases are turning up in other populations — and that number is likely to grow if public health officials don’t effectively nip the outbreak in the bud.
KHN’s ‘What the Health?’: Drug Price Bill Is a Go in the Senate
Two things happened in Washington this week that were inevitable: President Joe Biden tested positive for covid-19, and the Senate agreed to move forward on a budget bill that includes only a sliver of what Biden hoped it would. Still, the bill to allow Medicare to negotiate some drug prices, cap out-of-pocket drug costs for seniors, and extend temporary subsidies for Affordable Care Act insurance premiums would represent a major step if Democrats can get it across the finish line. Meanwhile, abortion battles continue to escalate around the country, with Texas leading the way in restrictions. Shefali Luthra of The 19th, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Jack Resneck Jr., the new president of the American Medical Association.
Critics Worry Government Surveillance of HIV May Hurt More Than It Helps
Some people living with HIV and some state health officials are raising concerns about part of the federal effort to end the HIV epidemic: a new technology that analyzes blood samples to find emerging outbreaks. The critics say it’s too invasive and stigmatizing and might not be more effective than older public health approaches.
Watch: Why the Public Health System Is Having Trouble Containing Monkeypox
KHN Midwest correspondent Lauren Weber appeared on CBS News’ streaming network to discuss “Fighting Monkeypox, Sexual Health Clinics Are Underfunded and Ill-Equipped,” an article she wrote with KHN senior correspondent Liz Szabo. It details how ill-equipped the nation’s sexual health clinics and public health system are to tackle monkeypox after decades of underfunding. Weber described […]
Fighting Monkeypox, Sexual Health Clinics Are Underfunded and Ill-Equipped
Sexual health clinics are scrambling to properly track, test, and treat hundreds of monkeypox patients. So far, it isn’t going well.
Las clínicas de salud sexual luchan sin medios contra la viruela del simio
Las clínicas que tratan las enfermedades de transmisión sexual —que ya se enfrentaban a un aumento explosivo de enfermedades como la sífilis y la gonorrea— se encuentran ahora en la primera línea de la lucha para controlar el brote de viruela del simio, que crece rápidamente.
Conservative Blocs Unleash Litigation to Curb Public Health Powers
Spurred on by opposition to pandemic-related health mandates, a coalition of religious liberty groups, conservative think tanks, and Republican state attorneys general has filed a cascade of litigation seeking to rein in the powers of public health authorities.
Boost Now or Wait? Many Wonder How Best to Ride Out Covid’s Next Wave
As the country faces a rise in new infections driven by the omicron BA.5 subvariant of the coronavirus, about 70% of people 50 and older who got a first covid-19 booster shot haven’t received the recommended second one, according to the Centers for Disease Control and Prevention. Many undervaccinated Americans have lost interest, and others aren’t sure whether to get boosted again now or wait for vaccines reformulated to target newer strains of the virus.
¿Ponerse el refuerzo ahora o esperar? Muchos se preguntan cómo navegar la próxima ola de covid
Aproximadamente el 70% de los estadounidenses de 50 años o más que recibieron una primera vacuna de refuerzo contra covid, y casi la misma cantidad de personas de 65 años o más, no han recibido un segundo, según datos de los CDC.